Akane Ariga, Seiichi Matsumoto, Taisuke Tanizawa, Keiko Hayakawa, Yusuke Minami, Masanori Saito, Norio Kurosawa, Kyoko Yamashita, Takashi Terauchi, Keisuke Ae
Journal: Medicine 2023;102(28):e34196
PMID: 37443509
RATIONALE
Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is considered a reliable and indispensable imaging method when evaluating distant metastases and clinical staging of angiosarcomas. Here, we report 2 cases of angiosarcoma with bone metastases with "false negative" findings on 18F-FDG PET/CT.
PATIENT CONCERNS
Case 1, a 39-year-old woman, who had undergone mastectomy for primary angiosarcoma 2 years prior, presented with a 5-month history of right coxalgia. Case 2 was a 37-year-old woman, who had undergone mastectomy for primary angiosarcoma 4 months prior. During postoperative follow-up, multiple bone lesions were detected on magnetic resonance imaging (MRI).
DIAGNOSES
Based on the histopathological findings, both cases were diagnosed with bone metastases of angiosarcoma. Although MRI showed multiple bone metastatic lesions, 18F-FDG PET/CT showed no uptake or osteolytic destruction in both cases.
INTERVENTIONS
Weekly paclitaxel was initiated as a salvage chemotherapy in both cases.
OUTCOMES
No uptake or osteolytic lesions were observed on 18F-FDG PET/CT, despite multiple bone metastases detected on MRI.
LESSONS
False-negative findings on 18F-FDG PET/CT should be considered when evaluating bone metastases of angiosarcoma. Even with negative findings on 18F-FDG PET/CT, open biopsy should be performed if MRI indicates bone metastases.
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.